

### Worldwide incidence

#### Introduction

The incidence of schizophrenia refers to how many new cases there are per population in a specified time-period, usually reported as the number of new cases per 100,000 people per year. It is different from prevalence, which refers to how many existing cases there are at a particular point in time.

#### Method

We have included only systematic reviews with detailed literature search, methodology, and inclusion/exclusion criteria that were published in full text, in English, from the year 2000. Reviews were identified by searching the MEDLINE, EMBASE, databases PsycINFO. Reviews with pooled data are prioritized for inclusion. Reviews reporting fewer than 50% of items on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA1) checklist have been excluded from the library. The evidence was araded auided bν the Grading Recommendations Assessment, Development and Evaluation (GRADE) Working Group approach<sup>2</sup>. The resulting table represents an objective summary of the available evidence, although the conclusions are solely the opinion of staff of NeuRA (Neuroscience Research Australia).

#### Results

We found two systematic reviews that met our inclusion criteria<sup>3, 4</sup>.

- Moderate to high quality evidence suggests the incidence rate of schizophrenia is around 18.58 per 100,000 person-years.
- Moderate quality evidence suggests the incidence of schizophrenia or schizophreniform disorder is around 14.55 per 100,000 person-years.



## Worldwide incidence

SCHIZOPHRENIA LIBRARY

Castillejos MC, Martín-Pérez C, Moreno-Küstner B

A systematic review and meta-analysis of the incidence of psychotic disorders: the distribution of rates and the influence of gender, urbanicity, immigration and socio-economic level

Psychological Medicine 2018; 48: 2101-15

View review abstract online

Comparison	The incidence of schizophrenia drawn from population-based studies carried out on the general population residing within a defined catchment area that were published between 2000 and 2015.
Summary of evidence	Moderate quality evidence (large sample, inconsistent, imprecise, direct) suggests the incidence rate of schizophrenia or schizophreniform disorder is around 14.55.
Diagnosis of schizophrenia or schizophreniform disorder	
7 studies, incidence rate = 14.55, 95%CI 2.81 to 26.30	
Consistency in results <sup>‡</sup>	Authors report data are inconsistent.
Precision in results§	Imprecise
Directness of results	Direct

Jongsma HE, Turner C, Kirkbride JB, Jones PB

International incidence of psychotic disorders, 2002-17: a systematic review and meta-analysis

The Lancet Public Health 2019; 4: e229-e44

View review abstract online

Comparison	The incidence of schizophrenia drawn from first-contact studies, cohort studies, case register studies, and studies with a general population register covering an entire health system, that were published between 2002 and 2017.	



## Worldwide incidence



Summary of evidence	Moderate to high quality evidence (large samples, inconsistent, precise, direct) suggests the incidence rate of schizophrenia is around 18.58.	
Diagnosis of schizophrenia		
26 studies, incidence rate = 18.58, 95%Cl 15.08 to 22.89, l <sup>2</sup> = 99%		
IR = 40.67), and in case re	ation register studies (3 studies, IR = 32.83), in cohort studies (2 studies, gister studies (3 studies, IR = $41.04$ ). The rate was lower in first contact studies, IR = $13.07$ ). The rate did not change over time.	
Consistency in results	Inconsistent	
Precision in results	Precise	
Directness of results	Direct	

## **Explanation of acronyms**

CI = confidence interval,  $I^2$  = the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (chance), IR = incidence rate

# Neural Ne

# SCHIZOPHRENIA LIBRARY

## Worldwide incidence

### Explanation of technical terms

\* Bias has the potential to affect reviews of both RCT and observational studies. Forms of bias include; reporting bias - selective reporting of results, publication bias - trials that are not formally published tend to show less effect than published trials, further if there are statistically significant differences between groups in a trial, these trial results tend to get published before those of trials without significant differences; language bias - only including English language reports; funding bias - source of funding for the primary research with selective reporting of results within primary studies; outcome variable selection bias; database bias including reports from some databases and not others; citation bias - preferential citation of authors. Trials can also be subject to bias when evaluators are not blind to treatment condition and selection bias of participants if trial samples are small<sup>5</sup>.

† Different effect measures are reported by different reviews.

Prevalence refers to how many existing cases there are at a particular point in time. Incidence refers to how many new cases there are per population in a specified time period. Incidence is usually reported as the number of new cases per 100,000 people per year. Alternatively some studies present the number of new cases that have accumulated over several years against a person-years denominator. This denominator is the sum of individual units of time that the persons in the population are at risk of becoming a case. It takes into account the size of the underlying population sample and its age structure over the duration of observation.

Reliability and validity refers to how accurate the instrument is. Sensitivity is the proportion of actual positives that are correctly identified (100% sensitivity = correct identification of all actual positives) and specificity is the proportion of negatives that are correctly identified (100% specificity = not identifying anyone as positive if they are truly not).

Weighted mean difference scores refer to mean differences between treatment and comparison groups after treatment (or occasionally pre to post treatment) and in a randomised trial there is an assumption that both groups are comparable on this measure prior to treatment. Standardized mean differences are divided by the pooled standard deviation (or the standard deviation of one group when groups are homogenous) that allows results from different scales to be combined and compared. Each study's mean difference is then given a weighting depending on the size of the sample and the variability in the data. 0.2 represents a small effect, 0.5 a medium effect, and 0.8 and over represents a large effect<sup>5</sup>.

Odds ratio (OR) or relative risk (RR) refers to the probability of a reduction (< 1) or an increase (> 1) in a particular outcome in a treatment group, or a group exposed to a risk factor, relative to the comparison group. For example, a RR of 0.75 translates to a reduction in risk of an outcome of 25% relative to those not receiving the treatment or not exposed to the risk factor. Conversely, a RR of 1.25 translates to an increased risk of 25% relative to those not receiving treatment or not having been exposed to a risk factor. A RR or OR of 1.00 means there is no difference between groups. A medium effect is considered if RR > 2 or < 0.5 and a large effect if RR > 5 or < 0.26. InOR stands for logarithmic OR where a InOR of 0 shows no difference between groups. Hazard ratios measure the effect of an explanatory variable on the hazard or risk of an event.

# Neural Ne

# SCHIZOPHRENIA LIBRARY

## Worldwide incidence

Correlation coefficients (eg, r) indicate the strength of association or relationship between variables. They are an indication of prediction, but do not confirm causality due to possible and often unforseen confounding variables. An r of 0.10 represents a weak association, 0.25 a medium association and 0.40 and over represents strong а association. Unstandardised (b) regression coefficients indicate the average change in the dependent variable associated with a 1 unit change in the independent variable, statistically controlling for the other independent variables. Standardised regression coefficients represent the change being in units of standard deviations to allow comparison across different scales.

‡ Inconsistency refers to differing estimates of treatment effect across studies (i.e. heterogeneity or variability in results) that is not explained by subgroup analyses and therefore reduces confidence in the effect estimate. I2 is the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (chance) - 0% to 40%: heterogeneity might not be important, 30% to 60%: may represent moderate heterogeneity, 50% to 90%: may represent heterogeneity and substantial over is considerable heterogeneity. |2 can calculated from Q (chi-square) for the test of heterogeneity with the following formula;

$$I^2 = \left(\frac{Q - df}{Q}\right) \times 100\%$$

§ Imprecision refers to wide confidence intervals indicating a lack of confidence in the effect estimate. Based on GRADE recommendations, a result for continuous data (standardised mean differences, not weighted mean differences) is considered

imprecise if the upper or lower confidence limit crosses an effect size of 0.5 in either direction, and for binary and correlation data, an effect size of 0.25. GRADE also recommends downgrading the evidence when sample size is smaller than 300 (for binary data) and 400 (for continuous data), although for some topics, this criteria should be relaxed<sup>7</sup>.

Indirectness of comparison occurs when a comparison of intervention A versus B is not available but A was compared with C and B was compared with C that allows indirect comparisons of the magnitude of effect of A versus B. Indirectness population, of comparator and or outcome can also occur when the available evidence regarding a particular population, intervention, comparator, or outcome is not available so is inferred from available evidence. These inferred treatment effect sizes are of lower quality than those gained from head-to-head comparisons of A and B.



SCHIZOPHRENIA LIBRARY

## Worldwide incidence

#### References

- 1. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMAGroup (2009): Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *British Medical Journal* 151: 264-9.
- 2. GRADEWorkingGroup (2004): Grading quality of evidence and strength of recommendations. *British Medical Journal* 328: 1490.
- 3. Castillejos MC, Martín-Pérez C, Moreno-Küstner B (2018): A systematic review and meta-analysis of the incidence of psychotic disorders: the distribution of rates and the influence of gender, urbanicity, immigration and socio-economic level. *Psychological Medicine* 48: 2101–15.
- 4. Jongsma HE, Turner C, Kirkbride JB, Jones PB (2019): International incidence of psychotic disorders, 2002-17: a systematic review and meta-analysis. *The Lancet Public Health* 4: e229-e44.
- 5. CochraneCollaboration (2008): Cochrane Handbook for Systematic Reviews of Interventions. Accessed 24/06/2011.
- 6. Rosenthal JA (1996): Qualitative Descriptors of Strength of Association and Effect Size. *Journal of Social Service Research* 21: 37-59.
- 7. GRADEpro (2008): [Computer program]. Jan Brozek, Andrew Oxman, Holger Schünemann. *Version* 32 for Windows